BIOMAT Database Logo BIOMAT Database Logo

[Initiatives against visceral leishmaniasis]. 2010

Kristoffer Brodwall
Barneavdelinga, Alesund sjukehus, Norway. kristoffer.brodwall@gmail.com

UI MeSH Term Description Entries
D007898 Leishmaniasis, Visceral A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African. Black Fever,Kala-Azar,Fever, Black,Kala Azar,Visceral Leishmaniasis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000666 Amphotericin B Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela. Amphocil,Amphotericin,Amphotericin B Cholesterol Dispersion,Amphotericin B Colloidal Dispersion,Fungizone
D000981 Antiprotozoal Agents Substances that are destructive to protozoans. Schizonticides,Agents, Antiprotozoal
D014943 Global Health A multi- and interdisciplinary field concerned with improving health and achieving equity in health for all people. It transcends national boundaries, promotes cooperation and collaboration within and beyond health science fields, and combines population-based disease prevention with individually-based patient care. International Health Problems,World Health,International Health,Worldwide Health,Health Problem, International,Health Problems, International,Health, Global,Health, International,Health, World,Health, Worldwide,Healths, International,International Health Problem,International Healths,Problem, International Health,Problems, International Health

Related Publications

Kristoffer Brodwall
Miltefosine: great expectations against visceral leishmaniasis.
January 2003, Journal of postgraduate medicine,
Kristoffer Brodwall
Development of Vaccines against Visceral Leishmaniasis.
January 2012, Journal of tropical medicine,
Kristoffer Brodwall
Vaccination trial against canine visceral leishmaniasis. Phocean Veterinary Study Group on Visceral Leishmaniasis.
July 1989, Parasite immunology,
Kristoffer Brodwall
Some compounds active against experimental visceral leishmaniasis.
January 1959, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
Kristoffer Brodwall
Immunoprophylaxis and immunotherapy against experimental visceral leishmaniasis.
January 1999, Vaccine,
Kristoffer Brodwall
Membrane-acting biomimetic peptoids against visceral leishmaniasis.
March 2023, FEBS open bio,
Kristoffer Brodwall
Eugenol derived immunomodulatory molecules against visceral leishmaniasis.
October 2017, European journal of medicinal chemistry,
Kristoffer Brodwall
Antineoplastic drug, carboplatin, protects mice against visceral leishmaniasis.
January 2013, Parasitology research,
Kristoffer Brodwall
Nucleoside hydrolase DNA vaccine against canine visceral leishmaniasis.
January 2009, Procedia in vaccinology,
Kristoffer Brodwall
The challenges on developing vaccine against visceral leishmaniasis.
January 2016, Revista da Sociedade Brasileira de Medicina Tropical,
Copied contents to your clipboard!